Peter Dolan

Bristol-Myers Squibb

Peter R. Dolan, the 47-year-old chairman and CEO at Bristol-Myers Squibb Co. (BMY ) and a former marathon runner, has an athlete's endurance. The question these days is whether investors will allow him to finish his most challenging contest ever: fixing Bristol.

Since he took over in May, 2001, the stock has lost half its value. Dolan had been in the top job at Bristol, the world's seventh-largest drug company, only a few months when he struck a $2 billion deal with ImClone Systems Inc. (IMCL ) to co-develop and co-promote its cancer drug Erbitux. The Food & Drug Administration rejected ImClone's application just months later. How did Dolan miss the warning signs? He declined to comment. Dolan took a $367 million pretax write-down on the investment.

Then, in the fall Dolan announced Bristol would have to restate sales and earnings, primarily for 2000 through 2002, reallocating some $2 billion in sales. The SEC and the U.S. Attorney's Office in New Jersey are now investigating.

Dolan has shaken up management, including hiring a new CFO. But Bristol still faces sluggish sales growth. After these stumbles, Dolan may find this is one race he can't finish.

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE